Encouraged by in vitro resu!ts, we have assessed the in vivo activity of paromomycin (PRM) against Mycobacterium tuberculosis, multidrug-resistant (MDR) M. tuberculosis (resistant to isoniazid, rifampin, and streptomycin), and Mycobacterium avium complex in C57BL/6 mice and their beige counterparts. In all these experiments, PRM was effective in preventing mortalit from a mycobacterial infection and was significantly more active than the drug-free control (P < 0.0005) in reducing the CFU relative to the mean log CFU in the lungs, livers, and spleens of infected animals. In the drug-susceptible M. tuberculosis experiment, PRM given at 100 and 200 mg/kg of body weight was significantly less active than isoniazid at 25 mg/kg (P < 0.0005) in reducing the mean log CFU in the lungs, livers, and spleens of infected mice. In the MDR M. tuberculosis experiment, PRM given at 200 mg/kg was effective, relative to the drug-free control, in reducing the mean log CFU of an isolate ofM. tuberculosis resistant to isoniazid, rifampin, and streptomycin. In theM. avium complex experiment, PRM given at 200 mg/kg was as effective as amikacin at 50 mg/kg in reducing the mean log CFU in the lungs, livers, and spleens of infected mice. On the basis of our experiments, we believe that PRM has promising activity in vivo in the treatment of infections caused by M. tuberculosis, MDR M. tuberculosis, and M. avium complex.
Because of the increase in the number of worldwide cases of tuberculosis (1, 6) , the recent outbreaks of multidrug-resistant (MDR) tuberculosis (1, 2) , and the continuing problem of disseminated Mycobacterium avium infections in the AIDS population (4, 5, 10) , new agents with increased antimycobacterial activity must be developed. We previously demonstrated high in vitro activity of paromomycin (PRM), an older parenteral oligosaccharide aminoglycoside antibiotic (3, 8) , against a number of susceptible and MDR strains of Mycobacterium tuberculosis and M. avium complex. The MICs of PRM against 16 strains of M. tuberculosis obtained from the Centers for Disease Control and Prevention, Atlanta, Ga., ranged from <0.09 to 1.5 mg/liter; for the 21 strains of M. avium complex, the MICs of PRM ranged from <1.56 to 12.5 mg/liter (8) . In this paper, we report the in vivo activity of PRM against M. tuberculosis, MDR M. tuberculosis, and M. avium infections of C57BL/6 mice and their beige counterparts. "There was a significant difference between the drug-treated groups and the drug-free control.
MATERIALS AND METHODS
c There was a significant difference between the group receiving PRM at 200 mg/kg and the group receiving PRM at 100 mg/kg.
d There was a significant difference between the groups receiving PRM at 200 mg/kg and AMK at 50 mg/kg and the group receiving PRM at 100 mg/kg. I There was a significant difference between the group receiving AMK at 50 mg/kg and the groups receiving PRM at 100 and 200 mg/kg.
25 mg/kg was significantly more active than PRM at 100 and 200 mg/kg and drug-free controls in reducing the mean log CFU in the lungs, livers, and spleens of infected mice at 4, 8, and 12 weeks (P < 0.0005). Overall, PRM at 200 mg/kg was significantly more effective than PRM at 100 mg/kg (P < 0.0005). In addition, the overall CFU rose in the lungs, livers, and spleens of mice treated with PRM at 100 mg/kg in comparison with day-1 controls. The overall CFU also rose in the lungs and spleens of mice treated with PRM at 200 mg/kg in comparison with baseline counts. However, with the 200-mg/kg dose of PRM, the CFU in the livers declined slightly at 12 weeks (Table 1) .
MDR M. tuberculosis. Mortality from tubercUtlosis infection was 100% in the SM-treated mice at 8 weeks and 100% in the drug-free controls at 12 weeks. None of the PRM-treated mice had died from tuberculosis infection within 12 weeks postinfection.
PRM at 200 mg/kg caused a significant reduction in the mean log CFU in the lungs, livers, and spleens of infected mice at 4 and 8 weeks in comparison with drug-free controls (P < 0.0005). At 12 weeks, the lungs, livers, and spleens of PRMtreated mice showed a decrease in the mean log CFU of approximately 1.5 in comparison with week-8 mean log CFU. There appeared to be no cross-resistance between PRM and SM in the experiment (Table 2) .
M. avium complex. Mortality from disseminated M. avium complex infection was 71% (5 of 7 mice) at 8 weeks in the drug-free controls. None of the drug-treated mice had died from disseminated M. avium complex infection within 8 weeks postinfection.
CFU were significantly lower in the lungs, livers, and spleens of mice treated with PRM at 100 and 200 mg/kg and AMK at 50 mg/kg than in drug-free control mouse organs at 4 and 8 week-s postinfection (P < 0.0005). By week 8 of the experiment, there was no statistically significant difference between PRM at 200 mg/kg and AMK at 50 mg/kg in reducing the mean log CFU in the lungs, livers, and spleens of infected animals. PRM at 200 mg/kg was significantly more active in the livers and spleens than PRM at 100 mg/kg at 4 weeks (P < 0.0005), and both PRM at 200 mg/kg and AMK at 50 mg/kg were significantly more active than PRM at 100 mg/kg in reducing the mean log CFU in the livers and spleens at 8 weeks (P < 0.0005). However, AMK at 50 mg/kg was more active than PRM at 100 mg/kg and PRM at 200 mg/kg in reducing the mean log CFU in the spleens at 4 weeks (P < 0.0005). Both doses of PRM were effective in reducing the mean log CFU in the lungs, livers, and spleens of infected animals in comparison with day-1 controls (Table 3) . DISCUSSION PRM, a broad-spectrum aminoglycoside structurally related to other oligosaccharide antibiotics, such as neomycin, kanamycin, and SM, has good in vitro activity against M avium complex and M tuberculosis, including MDR strains (8) . In the present study of its in vivo activity, PRM was active against the tested strains of M avium complex, M tuberculosis, and MDR M tuberculosis. The in vivo activity of PRM against the susceptible M tuberculosis strain was not comparable to that of INH. This result could be due to the fact that the aminoglycosides as a class have poor tissue penetration. However, PRM showed excellent in vivo activity against a known MDR M tuberculosis strain. In addition, PRM did not show any in vivo cross-resistance with SM.
On the basis of our preliminary findings, it appears that PRM has in vivo activity similar to that of SM. Its activity, like that of SM, may be more evident in combinations with other drugs (7, 9) . In addition to its high in vitro and in vivo activities, PRM has a low toxicity profile and a lack of cross-resistance with other antimycobacterial aminoglycosides. We believe that parenteral PRM may offer great promise in the treatment of mycobacterial diseases, especially those caused by MDR M tuberculosis. However, in vivo studies with additional M avium complex, M tuberculosis, and MDR M tuberculosis strains must be performed before any definite conclusions can be drawn. Because of the urgent need to develop new compounds which are active against mycobacteria, especially MDR M tuberculosis, PRM should be explored further as a new antimycobacterial agent.
